Second, we investigated the β- to α-signature shift in patients exposed to single or double drug-blockade (BRAFi or BRAFi + MEKi) by classifying their melanoma biopsies during the medication course (before, during, and at relapse) according to differentiated states (U, N, T, M) (Fig. 3g) and AhR-associated signatures (β-, α-, and resistance) (Fig. 3h). The gene discussed is AHR; the disease is melanoma.